Europe Markets: Bayer shares plunge by more than 20% after trial of potential blockbuster drug halted

Bayer lost a fifth of its market value at one point Monday, after the German pharmaceutical and agricultural group said it had ended a late-stage test for the anti-thrombotic drug asundexian due to a lack of efficacy.
Read Full Story

Author
Recent Posts

Market Watch

Latest posts by Market Watch (see all)

Outside the Box: Here’s how to know if your mutual fund sees ESG investing clearly - December 9, 2023
The Fed: Fed will try to ‘Keep calm and carry on’ amidst talk of steep rate cuts and recession - December 9, 2023
The Number One: This family just bumped Walmart’s Waltons as the richest in the world - December 9, 2023

Europe Markets: Bayer shares plunge by more than 20% after trial of potential blockbuster drug halted

SKIN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that The Beauty Health Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Recommended

FTCH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Farfetch Limited Investors with Substantial Losses Have Opportunity to Lead Case

Outside the Box: Here’s how to know if your mutual fund sees ESG investing clearly

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

FSR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fisker Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Need A Business Loan? Borrow From A ForexTV Certified Partner

Welcome Back!

Retrieve your password